Garadacimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Coagulation factor XIIa |
| Clinical data | |
| Trade names | Andembry |
| Other names | CSL-312, garadacimab-gxii |
| AHFS/Drugs.com | andembry |
| License data |
|
| Routes of administration | Subcutaneous, |
| Drug class | Bleeding suppressant |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
Garadacimab, sold under the brand name Andembry, is a human monoclonal antibody used for the treatment of hereditary angioedema. Garadacimab is a monoclonal antibody against the activated coagulation factor XIIa (FXIIa), with potential anti-inflammatory and anticoagulant activities.
Garadacimab is a fully human, recombinant, IgG4 lambda monoclonal antibody that binds to the catalytic domain of activated factor XII (FXIIa). FXIIa is the first factor activated in the contact system, which leads to the production of bradykinin. The inhibition of FXIIa therefore prevents the activation of prekallikrein into kallikrein and the generation of bradykinin, which is associated with inflammation and swelling in attacks of hereditary angioedema.
Garadacimab was authorized for medical use in the European Union in February 2025, and approved in the United States in June 2025.